Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Improvement with roflumilast foam was seen early, with roflumilast separating statistically from vehicle on IGA Success at week two.
- Improvement with roflumilast foam was seen early, with roflumilast separating statistically from vehicle on IGA Success at week two.
- In addition, more than 50% of patients treated with roflumilast foam achieved an IGA score of clear at week eight.
- Roflumilast foam also demonstrated statistically significant improvements compared to vehicle on key secondary endpoints, including itch, scaling, and redness (erythema).
- We are excited that investigational roflumilast foam demonstrated strong topline results in our pivotal Phase 3 trial, consistent with previously reported data.